# Title:

# Skeletal Muscle mTORC1 Activation Increases Energy Expenditure and Reduces Longevity in Mice

**Author names and affiliations:**

Erin J. Stephenson1,2,4, JeAnna R. Redd1,4,5, Detrick Snyder5, Quynh T. Tran3, Binbin Lu8, Matthew J. Peloquin1,4, Molly C. Mulcahy5, Innocence Harvey1,5, Kaleigh Fisher7, Joan C. Han1,2,4, Nathan Qi6,7, Alan R. Saltiel8,9 and Dave Bridges\*,1,2,4,5,8

1. Department of Physiology, University of Tennessee Health Science Center, Memphis, Tennessee, U.S.A.
2. Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, U.S.A.
3. Department of Preventative Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, U.S.A.
4. Children’s Foundation Research Institute, Le Bonheur Children’s Hospital, Memphis, Tennessee, U.S.A.
5. Department of Nutritional Sciences, University of Michigan School of Public Health, Ann Arbor, Michigan, U.S.A.
6. Department of Molecular & Integrative Physiology, University of Michigan Medical School, Ann Arbor, Michigan, U.S.A.
7. Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, U.S.A.
8. Life Sciences Institute, University of Michigan Medical Center, Ann Arbor, Michigan, U.S.A.
9. Institute for Diabetes and Metabolic Health, University of California San Diego, San Diego, California, U.S.A.

\* Corresponding author

**Corresponding author:**

Dave Bridges Email address: [davebrid@umich.edu](mailto:davebrid@umich.edu)

Postal address: 3866 SPH I 1415 Washington Heights Ann Arbor, Michigan 48109-2029 Telephone: +1 (734) 764-1266

**Declaration of Interests**

The authors have no competing interests to declare, except JCH, who is a consultant for Rhythm Pharmaceuticals.

# Abstract:

*Objective*

The mechanistic target of rapamycin (mTORC1) is a nutrient responsive protein kinase complex that helps co-ordinate anabolic processes across all tissues. There is evidence that signaling through mTORC1 in skeletal muscle may be a determinant of energy expenditure and aging and therefore components downstream of mTORC1 signaling may be potential targets for treating obesity and age-associated metabolic disease. This study aimed to identify mTORC1-dependent mechanisms in skeletal muscle that regulate energy balance and aging.

*Methods*

We generated mice with *Ckmm-Cre* driven knockout of *Tsc1,* which confers constitutive activation of mTORC1 in skeletal muscle and performed unbiased transcriptional analyses to identify pathways and candidate genes that may explain how skeletal muscle mTORC1 activity regulates energy balance and aging.

*Results*

Activation of skeletal muscle mTORC1 produced a striking resistance to diet- and age-induced obesity without inducing systemic insulin resistance. We found that increases in energy expenditure following a high fat diet were mTORC1-dependent and that elevated energy expenditure caused by ablation of *Tsc1* coincided with the upregulation of skeletal muscle-specific thermogenic transcriptional changes that suggest a role for sarcolipin-driven futile cycling of Ca2+ through SERCA2. With respect to longevity, we show that ablation of *Tsc1* in skeletal muscle reduces organismal lifespan.

*Conclusions*

These findings support the hypothesis that activation of mTORC1 and its downstream targets, specifically in skeletal muscle, may play a role in nutrient-dependent thermogenesis and aging.

**Key words**: Skeletal muscle, Energy expenditure, Thermogenesis, mTORC1, aging, obesity

# 1.0 Introduction

Obesity is a worldwide health problem, with comorbidities including diabetes, cardiovascular and liver disease (97). At the root of obesity is impaired energy balance, or a combination of elevated energy intake and reduced energy expenditure. Genetic and dietary modifiers of energy expenditure are not well understood, but there is evidence that signaling through the mechanistic Target of Rapamycin Complex 1 (mTORC1) may play a role (35, 36, 58, 93). As a nutrient and energy sensing kinase, this hypothesis is attractive since it is well established that in response to elevated caloric intake, energy expenditure increases (1, 24, 53). This physiological adaptation allows for stable control of body composition. This may be of clinical significance, as individuals with elevated adaptive thermogenic responses to weight loss tend to have more difficulty sustaining the reduced body size (41, 78).

mTORC1 is a nutrient responsive protein kinase complex expressed in all known eukaryotic cells. This complex is activated by anabolic signals including insulin, amino acids and energy abundance, and repressed during periods of energy and nutrient deprivation (see (27) for review). mTORC1 integrates these signals, and helps co-ordinate anabolic processes such as protein synthesis, lipogenesis (19, 54, 98), glycogenesis (60) and cellular differentiation (28, 40, 100), while also promoting insulin resistance (84, 98). These effects are often tissue-specific, reflecting the cell-type specific responses to elevated nutrient and energy status.

Skeletal muscle is the major site of postprandial glucose disposal and the primary determinant of resting energy expenditure in mammals (23, 80). Constitutive activation of mTORC1, via muscle-specific deletion of its negative regulator *Tsc1*, results in age-related myoatrophy, dysregulation of autophagy induction and increased expression of mitochondrial enzymes (10, 17, 36). Consistent with the latter, cell culture models implicate mTORC1 as a positive regulator of mitochondrial biogenesis and aerobic ATP production (22, 47, 75). During the aging process, skeletal muscle exhibits a fiber-type transformation towards a more oxidative phenotype, concomitant with increased mTORC1 activity. In line with these observations, several studies have implicated mTORC1 inhibition as a mechanism of organismal lifespan extension in yeast, worms and mammals (15, 38, 45); however, the tissue or tissues that link mTORC1 activity to lifespan have not yet been identified.

Skeletal muscle is an important tissue for understanding aging, insulin sensitivity and changes in energy metabolism, as functional differences in muscle strength predict lifespan in humans (32, 57, 64, 76, 77, 83). Furthermore, mTORC1 regulates several important metabolic processes in muscle; including oxidative stress, the unfolded protein response, autophagy and lipid metabolism (10, 51, 66). Here, we have performed unbiased transcriptional analyses to identify pathways and candidate genes that may explain how skeletal muscle mTORC1 activity regulates energy balance and aging. We show that chronic mTORC1 activation in skeletal muscle (via deletion of its negative regulator, *Tsc1*) promotes increased energy expenditure, but reduced lifespan.

# 2.0 Materials and Methods

## 2.1 Animals

All mice were purchased from The Jackson Laboratory. Unless otherwise stated, animals were fed a normal chow diet from Harlan Teklad (catalog # 7912). For high fat diet (HFD) studies, animals were provided *ad libitum* accessto a diet with 45% of calories from fat (Research Diets D1492). HFD feeding was initiated when animals were approximately 10 weeks of age. For tissue collection, animals were anesthetized with isoflurane before being sacrificed by cervical dislocation at 25 weeks of age.

Muscle-specific *Tsc1* knockouts were generated by crossing FVB-Tg(*Ckmm*-*Cre*)5Khn/J transgenic mice (stock 006405) with floxed *Tsc1tm1Djk*/J mice (stock 005680). To generate F1 mice that were heterozygous for the floxed allele, mice that either possessed or lacked the *Ckmm-Cre* transgene were intercrossed to generate knockout mice (*Tsc1fl*/fl, *Ckmm-Cre*Tg/+), wild type mice (*Tsc1+/+*, *Ckmm-Cre*+/+) and controls containing the transgene only (*Tsc1+/+*, *Ckmm-Cre*Tg/+), or the floxed allele only (*Tsc1fl*/fl, *Ckmm-Cre*+/+). All four genotypes were studied in all experiments. If there were no significant differences between the three control genotypes, these results were combined and labeled as wild-type. Animals were sacrificed in either the fed or fasted state as indicated in the figure legends, at approximately ZT3. All animal procedures were carried out in accordance with the National Institute of Health guide for the care and use of Laboratory animals and were approved by The University of Michigan and UTHSC Institutional Animal Care and Use Committees prior to the work being performed.

## 2.2 Body Composition and Indirect Calorimetry

Body weights were determined using a standard scale, whereas body composition was determined in conscious animals by magnetic resonance (EchoMRI 1100, EchoMRI, Houston, TX). Adipose tissue weights (dorsolumbar-inguinal and gonadal depots) were dissected from both the left and right sides (the combined weight of both sides is reported). For indirect calorimetry studies, physical activity, VO2 and VCO2 were determined using a home-cage style Comprehensive Laboratory Animal Monitoring System (CLAMS, Columbus Instruments, Columbus, OH) with hanging feeders containing pelleted food, under light and temperature-controlled conditions (12:12hr, 25ºC). Ambulatory activity was calculated as the sum of x and y axis beam breaks. The first 6h of CLAMS measurements were discarded to accommodate acclimation, after which continuous measurements were made over three consecutive days. Data were analyzed by mixed linear models with considerations (88, 95). To account for the dominant effect of lean mass on total energy expenditure, lean mass was included as a covariate in the mixed linear models. Energy expenditure was calculated as heat, using the Lusk equation in Oxymax software (Columbus Instruments, Columbus, OH), and rates of carbohydrate and lipid oxidation were calculated according to Péronnet and Massicotte (71) with the assumption that the rate of protein oxidation occurring under standard housing conditions is negligible. For rapamycin treatments, animals were individually housed for 10 consecutive days (days 3-10 were in CLAMS cages). Mice received four days of vehicle treatment (1% Tween, 1% PEG-8000), followed by three days of treatment with either vehicle or the selective mTOR inhibitor rapamycin (3 mg/kg/d, via intraperitoneal injection). Mice were then switched to HFD and indirect calorimetry measurements continued for an additional three days, during which time mice continued to receive daily injections of either vehicle or rapamycin.

## 2.3 Hyperinsulinemic Euglycemic Clamp and Tissue 2-Deoxyglucose Uptake

Animals were anesthetized with sodium pentobarbital (50−60 mg/kg, given intraperitoneally) and indwelling catheters were implanted into the right jugular vein and the right carotid artery. The catheters were tunneled subcutaneously and exteriorized at the back of the neck via a stainless-steel tubing connector that was fixed subcutaneously upon closure of the incision. Animals were allowed to recover and mice with healthy appearance, normal activity, and weight regain to or above 90% of their pre-surgery levels were used for the study. Experiments were carried out in conscious and unrestrained animals using techniques described previously (5, 37, 39, 63). The primed (1.0 µCi)-continuous infusion (0.05 µCi/min and increased to 0.1 µCi/min at t = 0) of [3-3H] glucose (50 µCi/ml in saline) was started at t = -120min. After a 5-6 hour fast, the insulin clamp was initiated at t = 0, with a prime-continuous infusion (40 mU/kg bolus, followed by 2.5 mU/kg/min) of human insulin (Novo Nordisk). Euglycemia (120~130 mg/dL) was maintained during the clamp by measuring blood glucose every 10 min and infusing 50% glucose at variable rates, accordingly.  Blood samples were collected from the right carotid artery at t = 80, 90, 100, and 120 min for determination of glucose specific activity.  Blood insulin concentrations were determined from samples taken at t = -10 and 120 min. A bolus injection of [1-14C]-2-deoxyglucose ([14C]2DG; PerkinElmer) (10 µCi) was given at t = 120 min. Blood samples were taken at 2, 5, 10, 15, and 25 min after the injection for determination of plasma [14C]2DG radioactivity. At the end of the experiment, animals were anesthetized with an intravenous injection of sodium pentobarbital and tissues were collected and immediately frozen in liquid nitrogen for later analysis of tissue [1-14C]-2-deoxyglucose phosphate ([14C]2DGP) radioactivity. Blood glucose was measured using an Accu-Chek glucometer (Roche, Germany). Plasma insulin was measured using the Linco rat/mouse insulin ELISA kits.  For determination of plasma radioactivity of [3-3H]glucose and [1-14C]2DG, plasma samples were deproteinized with ZnSO4 and Ba(OH)2 and counted using a Liquid Scintillation Counter (Beckman Coulter LS6500 Multi-purpose Scintillation Counter). Glucose turnover rate, hepatic glucose production and tissue glucose uptake were calculated as described elsewhere (5, 37, 48).

## 2.4 Insulin Tolerance Test

Insulin tolerance tests were performed in high fat fed mice at 24 weeks of age. The day prior to the test, body composition was determined by magnetic resonance (Echo MRI1100, Houston, TX) and lean mass values were used to calculate insulin dose (1 U/kg of lean mass; Humulin R-100, Lilly, U.S.A). On the day of the test, fasting blood glucose concentrations were determined following a 6 hr fast, after which mice received an intraperitoneal injection of insulin diluted in sterile PBS. Blood glucose concentrations were measured every 15 min over a two-hour period post-injection (One Touch Ultra2 hand-held glucometer, LifeScan Europe, Zug, Switzerland).

**2.5 RNA Sequencing Analysis and Bioinformatics**

Total RNA was extracted from *m. quadriceps femoris* using a Pure Link RNA mini kit (Life Technologies) and then analyzed using an Agilent Bioanalyzer DNA High Sensitivity kit. All samples had a RNA Integrity numbers >7.9. The RNA (1 μg) was enriched for Poly A RNA using an Ambion Dynabeads mRNA Direct Micro kit and barcoded libraries for sequencing were prepared using the Life Technologies RNAseq V2 kit for Ion Torrent according to manufacturer’s standard protocol. The libraries were pooled based on the concentration of each sample between 200-350bp, purified on a Pippin Prep gel, quantified by the Agilent Bioanalyzer and sequenced on an Ion Torrent Proton sequencer. Alignments were made to the mouse genome GRCm38.75 using Tophat 2.0.10 (46) and Bowtie 1.0.0 (50) to incorporate color space data. Counts tables were generated using HTSeq version 0.5.4p5 (2). Differential expression analyses were performed using DESeq2 version 1.20.0 (59). All results are presented in Supplementary Table 1, and deposited into the Gene Expression Omnibus as GSE84312. To compare our results to other gene-sets we performed Gene Set Enrichment Analyses (GSEA) comparing our rank-ordered gene lists to annotated gene sets from Gene Ontology, KEGG, Biocarta, Reactome, TRANSFAC and CGP provided as part of MSigDB v6.2 (56, 89). All pathways that met significance at an adjusted p-value of 0.25 are presented in Supplementary Table 2. For comparison of differentially expressed genes, we re-analyzed the *Tsc2* knockout MEFs from GSE21755 (26) and compared with our differentially regulated gene sets.

## 2.6 Western Blotting

Protein lysates were generated from *m. quadriceps femoris* in RIPA buffer (50 mM Tris pH 7.4, 0.25% sodium deoxycholate, 1% NP40, 150 mM sodium chloride, 1 mM EDTA, 100 μM sodium vanadate, 5mM sodium fluoride, 10 mM sodium pyrophosphate and 1X protease inhibitors) or HTNG buffer (50 mM HEPES, pH 7.4, 150 mM sodium chloride, 10% glycerol, 10% triton X-100 and 1X protease inhibitors) by mechanical disruption in a Qialyser for 5 minutes at 30Hz. Lysates were clarified at 14 000 RPM for 15 minutes and quantified by Bradford assays. Proteins were separated by SDS-PAGE, transferred to nitrocellulose and blotted with antibodies described in the figure legends. Primary antibodies used in this study were raised against pS6 (pSer236/236, Cell Signaling #2211), S6 (Cell Signaling #2317), GAPDH (Proteintech #10494) and Sarcolipin (EMD Millipore #ABT-13). Near infra-red secondary antibodies raised against rabbit (Alexa Fluor #A21109) and mouse (Alexa Fluor 790 #A11371) were used to visualize blots on a LiCor Odyssey. Relative protein abundance was quantified using Image Studio Lite software.

## 2.7 NADH Tetrazolium Reductase Staining

## For histology, muscles (*m. quadriceps femoris*) were frozen in liquid nitrogen-cooled isopentane, mounted in OTC and sectioned using a cryostat to 10 µm thickness. Frozen sections were incubated at 37°C for 30 min in pre-warmed 200 mM Tris buffer pH7.4, containing 245 µM nitro blue tetrazolium and 1.13 mM NADH. Sections were rinsed in water, dehydrated, and mounted under coverslips. Staining was visualized and photographed using an Evos XL Core transmitted-light inverted imaging system (Thermo Fisher Scientific).

## 2.8 Statistical Analyses

All statistical analyses were performed using R, version 3.2.2 (74). For longitudinal measurements (body weights, fat mass and lean mass), data were analyzed by mixed linear models using uncorrelated random slopes and intercepts using the lme4 package version 1.1-8 (8). Statistical significance was determined via likelihood ratio tests between models containing or missing the genotype term. Pairwise comparisons were tested for normality via a Shapiro-Wilk test, and for equal variance via Levene’s test. For survival analyses and Cox proportional hazard tests, the survival package was used (version 2.38-3, (91, 92)). We tested the assumptions of proportional hazards (with Shoenfeld residuals) and found no significant deviation from this assumption (p=0.875). Based on these, appropriate pairwise tests were performed as indicated in the figure legends. Corrections for testing of multiple hypotheses were done using the method of Benjamini and Hochberg (9). Statistical significance was designated at p/q<0.05 for all assays, except GSEA analyses where q<0.25 was used. All raw data and statistical analyses for this manuscript are available at <http://bridgeslab.github.io/TissueSpecificTscKnockouts>.

# 3.0 Results

## 3.1 Rapamycin Treatment Blunts High Fat Diet-Induced Increases in Energy Expenditure

To test whether mTORC1 plays a role in the short-term thermogenic responses to obesogenic diets, we measured the total energy expenditure of C57BL6/J mice during a dietary shift between low fat (chow) and HFD in the presence or absence of the specific mTOR inhibitor rapamycin. As depicted in Figure 1A, individually housed animals were vehicle-injected daily for four days, followed by three days of either vehicle or rapamycin injection. After three days of treatment, all animals were moved from a chow diet to HFD. As shown in Figure 1B, the switch to HFD caused an 8.1% increase in total energy expenditure in the vehicle injected mice during the dark phase and a 6.4% increase during the light phase. Compared to vehicle treated mice, rapamycin injection suppressed the HFD-induced increase in energy expenditure (p=2.1x 10-4). Notably, these effects were not associated with decreases in physical activity (Figure 1C). These data support the hypothesis that mTORC1 is required for the increase in energy expenditure observed in response to acute HFD feeding.

## 3.2 Activation of mTORC1 in Muscle Increases Energy Expenditure

To test whether skeletal muscle mTORC1 activation would result in increases in energy expenditure, we performed indirect calorimetry studies on *Ckmm-Cre* driven *Tsc1* knockout mice. These mice have elevated mTORC1 signaling, as determined by phosphorylation of S6 in all muscle tissues tested (quadriceps, tibialis anterior, extensor digitorum longus and heart), but no non-muscle tissues (brown and inguinal white adipose tissue, spleen, liver or kidneys) suggesting effective and muscle-specific mTORC1 activation (Supplementary Figure 1). We observed increased total energy expenditure in muscle specific *Tsc1* knockout mice (Figure 1D, p<1 x 10-6), and the magnitude of this difference was greater during the dark (active) phase (7.0% increase in males, 6.8% increase in females). Although the greatest energy expenditure differences primarily occurred during the active phase, we did not observe any differences in physical activity (Figure 1E­­­­). While there were no significant differences in the respiratory exchange ratio (RER) between knockout and control male mice (Figure 1F), female muscle *Tsc1* knockout mice had a lower RER during the dark period (suggestive of greater lipid utilization while active), and a higher RER during the light period (suggestive of greater carbohydrate utilization while resting) compared to their control counterparts. This finding is corroborated by rates of carbohydrate and lipid oxidation (Figure 1 G and H), and may suggest sexual dimorphism in how muscle mTORC1 signaling affects metabolic flexibility. Together, these data are consistent with a physiological role for mTORC1 in moderating organismal energy expenditure.

**3.3 Activation of mTORC1 in Muscle does not alter energy intake**

We next evaluated the effect of *Ckmm-Cre* driven *Tsc1* knockout on energy intake in animals receiving either standard laboratory chow or HFD. As shown in Figure 1I, mice receiving the HFD ingested more calories than mice receiving chow (p<0.001); however, there were no differences in energy intake between control and muscle *Tsc1* knockout mice within each diet (p=0.426), and no differences between sexes (p=0.785). While not significant, there was a slight elevation in the energy intake of male knockout mice receiving HFD, consistent with previous reports that show mice with *ACTA1-Cre* driven *Tsc1* knockout eat more food relative to their body weight than control mice when provided a diet consisting of 60% calories from fat (35).

## 3.4 Activation of mTORC1 in Muscle Causes Resistance to Age- and Diet-Induced Obesity

Given our finding that mTORC1 activation in skeletal muscle caused elevated energy expenditure in the absence of increased energy intake or physical activity, we sought to understand the physiological significance of mTORC1 activation on body composition. The body weights (Figure 2A) and composition (Figure 2B-C) of male muscle *Tsc1* knockout mice given a normal chow diet was determined weekly, over the course of 7 months. As animals aged, control mice accreted body fat, whereas fat mass gains were minimal in the knockout group; a striking 84% difference being observed between knockout and control groups (Figures 2B, p=1.7 x 10-10). Previous work using *ACTA1-Cre* mediated knockout of *Tsc1* also report lower body fat accumulation in knockouts compared to control mice (35, 36), concomitant with reductions in lean mass (17, 36). We did not observe reduced lean mass in our study (Figure 2C, p=0.743 at endpoint), likely due to our different Cre drivers. To determine if reductions in body fat gains were adipose depot-specific, we determined the weights of subcutaneous (dorsolumbar-inguinal) and visceral (epididymal) fat pads from male control and *Tsc1* knockout mice, and found that both fat depots were markedly lighter (decreased 79% and 76%, respectively, each p<0.0001; Figure 2D). Together, these findings demonstrate that skeletal muscle mTORC1 activation results in lower adiposity gains across the lifespan.

**3.5 Activation of mTORC1 in Muscle Does Not Induce Systemic Insulin Resistance**

Activation of mTORC1 has been reported to induce systemic insulin resistance in some systems, so we next determined insulin sensitivity in these mice by insulin tolerance test. As shown in Figure 2E, male knockout mice had similar insulin responsiveness to control mice. This was unexpected, as cell-based studies suggest improvement of insulin signaling with mTORC1 inhibition (12, 85, 94), though it is consistent with prior muscle *Tsc1* knockout models (35, 36). To understand this further, we performed hyperinsulinemic euglycemic clamps, and found similarly unchanged insulin sensitivity. The rate of glucose infusion during the clamp was not different in knockout mice, nor were glucose turnover rates (Figure 2F) or the accumulation of 2-deoxyglucose in gastrocnemius muscles (Figure 2G). 2-deoxyglucose uptake into brown adipose tissue was not different between knockout and control mice, whereas 2-deoxyglucose uptake into both subcutaneous and visceral white adipose tissue depots was markedly elevated.

To determine if a palatable, hypercaloric diet would induce changes in body composition or insulin sensitivity in mice with *Ckmm-Cre* driven knockout of *Tsc1*, we placed mice on a diet containing 45% of calories from fat and found that both male and female mice were resistant to HFD-induced weight gain. (Figure 3A) Differences in body weight were primarily due to differences in fat mass, which, compared to control mice, was 60% lower in knockout males and 58% lower in knockout females by the end of the study (Figure 3B, p<1.0x10-6 for each). These data are consistent with previous reports in *ACTA1-Cre* mediated *Tsc1* knockout mice fed a diet containing 60% calories from fat (35, 36); however, in our model lean masses across both sexes were not different between control and knockout mice on HFD (Figure 3C, p=0.941). Consistent with the *in vivo* body composition data, we observed a 75-80% difference in the weights of both the gonadal and inguinal fat pads from male and female knockout mice compared to their relative control groups (all p<0.001; Figure 3D). Together, these findings demonstrate that mTORC1 activation in skeletal muscle can protect against adiposity gains under otherwise obesogenic conditions.

As shown in Figure 3E, compared to control mice, both male and female muscle *Tsc1* knockout mice were more insulin responsive (33% reduction in the area under the blood glucose curve for females, 45% difference for male mice; p=0.045 and 0.014 respectively). This finding is consistent with the hypothesis that muscle *Tsc1* knockout mice are not lipodystrophic but have improved glycemic control in addition to reduced adiposity. We propose that mice with muscle *Tsc1* knockout are protected from HFD-induced adipose tissue expansion as a result of having chronically elevated energy expenditure, and that the attenuated body fat gains observed in muscle *Tsc1* knockout mice facilitates the preservation of insulin sensitivity in the face of a HFD.

## 3.6 Muscle mTORC1 Activation Causes Enrichment of Gene Sets Involved in Fatty Acid Uptake and Amino Acid Uptake

To gain further insight into the mTORC1 activity-driven mechanisms within skeletal muscle that increase energy expenditure and limit body fat accumulation in *Tsc1* knockout mice, we performed RNA sequencing studies in RNA obtained from *m. quadriceps femoris* from chow-fed male mice with *Ckmm-Cre* driven *Tsc1* knockout and their floxed litter mates. We identified 4403 differentially expressed gene transcripts in these animals, including 2464 upregulated genes and 1939 downregulated genes (see Supplementary Table 1 for complete list). To identify the pathways and networks associated with these differentially expressed gene transcripts, we performed gene-set enrichment analyses, finding 674 differentially regulated gene sets (see Supplementary Table 2). Among the significantly enriched gene sets were genes also regulated by *Tsc2* deletion in MEFs, and by treatment with rapamycin (14, 26), indicating there are a core set of mTORC1 dependent genes that are similarly regulated across different tissues. Consistent with this observation, we found that 58% of the differentially expressed genes in the *Tsc1* knockout muscles overlapped with previously published differentially expressed genes in *Tsc2* knockout MEFs (26). Other gene sets we identified as being upregulated by *Tsc1* ablation in skeletal muscle include IGF1 targets in MCF-7 cells (67), genes involved in protein synthesis, amino acid (Figure 4A) and fatty acid uptake (Figure 4B), and calcium trafficking (Figure 4C). Most amino acid transporters were increased at the mRNA level (Figure 4A), while the fatty acid binding protein *Fabp3* was also increased at the transcriptional level (Figure 4B).

## 3.7 Muscle mTORC1 Activation Increases Thermogenic Signaling via Alterations in Intramyocellular Ca2+ Dynamics

To identify the molecular mechanisms causing increased energy expenditure in muscle *Tsc1* knockout mice, we determined the expression of transcripts known to be important contributors to skeletal muscle thermogenesis. We observed dramatic increases in the ATP-dependent SR/ER Ca2+ pump SERCA2 (encoded by *Atp2a2*, see Figure 4C), and its un-coupler Sarcolipin (encoded by *Sln*; Figure 4C), proteins previously reported as playing an integral role in muscle-specific thermogenesis (6, 16, 62, 81). At the protein level, Sarcolipin was increased 4.1-fold (p=4.5 x 10-6; Figure 4D, pS6 is shown as a positive control for mTORC1 activation). We propose that the increased energy expenditure observed in mice with muscle-specific *Tsc1* ablation may be caused, in part, by increased futile cycling of Ca2+ by uncoupled SERCA2 (therefore increasing ATP hydrolysis) at the SR. Consistent with this hypothesis, we observed increases in the expression of other transcripts important for Ca2+ trafficking, including *Pln*, *Casq2,* *Stim1* (Figure 4C), *Mfn1-2* (Supplementary Table 1) and the subunits of the mitochondrial calcium importer (*Mcu, Micu1* and *Micu2*; Supplementary Table 1). We also observed reductions in *Ryr1,* *Calm1* and *Calm3* expression (Figure 4C), and reductions several plasma membrane Ca2+ transporters (see Supplementary Table 1), changes that are likely adaptive mechanisms to manage increased intracellular Ca2+ levels associated with SERCA2 uncoupling.

## 3.8 Constituent mTORC1 Activation Increases the Oxidative Profile of Skeletal Muscle

We also evaluated transcriptional markers of muscle fiber type and observed increases in markers for more oxidative fiber types, including *Myh7, Mb, Tnnc1, Tnni1* and *Atp2a2*, along with downregulation of markers for glycolytic fibers, including *Myh4, Pvalb, Tnnc2, Tnni2* and *Atp2a1* (Figures 4C and E, and Supplementary Table 1). These data suggest that skeletal muscle mTORC1 activation increases the oxidative profile of skeletal muscle at the transcriptional level. These findings are also supported by our observation that skeletal muscle from *Tsc1* ablated mice has greater NADH-dehydrogenase activity (Figure 4F), and are consistent with findings from previous studies on *ACTA1-Tsc1* knockout muscles that report the accumulation of mitochondrial enzymes and changes in muscle fiber size (10, 11).

## 3.9 Muscle mTORC1 Activation Reduces Lifespan

To determine whether skeletal muscle mTORC1 activation-induced increases in energy expenditure affected lifespan, we monitored muscle *Tsc1* knockout animals without manipulation as they aged. Increased signs of aging, including hunched and scruffy appearances, were observed at an earlier age in knockout mice compared to their control littermates. As shown in Figure 5, muscle-specific *Tsc1* knockout mice died of natural causes earlier than control mice. Based on a Cox-proportional hazard model, the hazard ratio was 4.17-fold higher compared to non-knockout littermates (p=2.0 x 10-5).

To determine how muscle *Tsc1* ablation reduces lifespan, a subset of mice were fixed in formalin upon death and sent for veterinary pathology. However, we were unable to identify a consistent cause of death in these mice. In mice with histologic evidence of lesions, the predominant process was neoplasia, and the specific etiology was lymphoma/lymphosarcoma affecting multiple organs, though this was only true for control mice (two out of four) but not knockout animals (none out of three). It is important to note that lack of a specific diagnosis does not necessarily confirm the lack of lesions in examined animals; rather, that autolysis and the small number of animals evaluated may have resulted in loss of identifiable processes or tissues in which an etiology was present in-life.

# 4.0 Discussion

Skeletal muscle is an important determinant of tissue insulin responsiveness, energy balance and healthy aging. Humans with high baseline grip strength have decreased risk of all-cause mortality (32, 57, 64, 76, 77, 83), whereas interventions that increase muscle mass and strength are associated with improved health outcomes in both young and older populations (4, 29). Given that skeletal muscle is also the primary determinant of resting energy expenditure, understanding the molecular mechanisms that influence skeletal muscle health could have important ramifications for the clinical treatment of diseases associated with both obesity and aging. Furthermore, this work points to a catabolic role of mTORC1, potentially as a homeostatic mediator of energy dissipation in nutrient stress. This work also points to the role of skeletal muscle as a major source of thermogenesis that could be leveraged to reduce obesity and metabolic disease.

In this work, we show that high fat diet-induced increases in energy expenditure are mTORC1-dependent. We also demonstrate that constitutive activation of skeletal muscle mTORC1 causes elevated total energy expenditure independent of changes in physical activity, and that mTORC1-driven increases in energy expenditure coincide with reduced adiposity, increased insulin responsiveness and the upregulation of skeletal muscle-specific thermogenic mechanisms that involve ATP-dependent futile cycling of Ca2+. Consistent with prior work (10, 36), we also show transcriptional evidence for an mTORC1-dependent fiber type transition to a more oxidative phenotype, along with other markers of altered substrate oxidation and energy transformation in skeletal muscle. One caveat to this work is that we rely on *Tsc1* ablation to activate mTORC1, and cannot exclude the possibility of non-mTORC1-dependent roles of *Tsc1* ablation in muscle.

Our understanding of how mTORC1 regulates skeletal muscle physiology largely consists of the translation-initiation and post-translational role of mTORC1 and its anabolic response to growth factors, nutrients and mechanical loading (27). Less is known regarding the role of mTORC1 in the regulation of skeletal muscle substrate oxidation and energy expenditure; however, it has been suggested that gene silencing of mTORC1 alters ATP generation through disruption of PGC-1α driven mitochondrial signaling *in vitro* (22), and that the increase in *Ppargc1a* expression that occurs in muscle during the acute post-exercise phase has been shown to be potentiated in mouse skeletal muscle when mTORC1 is inhibited by rapamycin (73). Previous studies have shown that activating mTORC1 in mice through deletion of *Tsc1* in skeletal muscle results in smaller mice that have significantly lower body fat than control mice and are resistant to both diet-induced obesity and age-associated gains in adiposity (35, 36). Our results agree with these data, and we provide evidence that resistance to the accretion of body fat in these animals may be conferred, in part, by an increase in energy expenditure caused by sarcolipin-driven uncoupling of SERCA2 in skeletal muscle.

Skeletal muscle thermogenic pathways are important contributors to both shivering and non-shivering thermogenesis and while mitochondrial-generated thermogenic pathways have been described as potential targets for leveraging skeletal muscle thermogenesis to combat obesity (13), other heat generating pathways may also be important. The Sarco/Endo-plasmic Reticulum Ca2+-ATPase (SERCA) transports Ca2+ from the sarcoplasm into the lumen of the sarcoplasmic reticulum, hydrolyzing ATP in the process. Sarcolipin, a small helical peptide, can interact with SERCA and alter the kinetics of Ca2+ re-sequestration by allowing slippage of Ca2+ back into the sarcoplasm, thereby ‘decoupling’ Ca2+ uptake from SERCA-dependent ATP hydrolysis and creating a futile cycle of Ca2+ movement that generates heat (86). In the present study, *Ckmm-Cre* driven *Tsc1* deletion resulted in increased whole-body energy expenditure (Figure 1D), transcriptional upregulation of both SERCA2 and sarcolipin (Figure 4C), and increased expression of sarcolipin at the protein level (Figure 4D). We predict that the increased amounts of sarcolipin in muscle *Tsc1* knockout mice result in increased SERCA2 uncoupling and higher rates of ATP-dependent futile Ca2+ cycling (6, 82), a hypothesis supported by our observation that a number of other Ca2+ transporters and Ca2+ responsive mRNA’s are differentially expressed in the muscles of these mice (Figure 4C and Supplementary Table 1). We propose that muscle thermogenesis through the sarcolipin-driven uncoupling of SERCA would increase organismal energy expenditure, thereby resulting in lower adiposity gains. Indeed, this hypothesis is consistent with reports that obesity is exacerbated when *Sln* is ablated (6, 16, 81) or prevented when it is *Sln* is overexpressed (62). Human cross-sectional studies demonstrate elevated Sarcolipin mRNA and protein alongside more inefficient fuel oxidation in muscle fibers (68). These data point to an important role for Sarcolipin as a potential mediator of weight-induced adaptive thermogenesis

In addition to the changes in Ca2+ related transcripts, we and others have observed that skeletal muscle-specific activation of mTORC1 via deletion of *Tsc1* results in an increase in the oxidative profile of the skeletal muscle (10). Furthermore, non-*Tsc1*-driven models of muscle-specific mTORC1 activation, such as those involving knockout of individual components of the GATOR1 complex, result in increased expression of mitochondrial components, particularly TCA cycle intermediates (25), and increased mitochondrial respiration (34). Conversely, abolishing skeletal muscle mTORC1 activity via Raptor knockout increases mitochondrial coupling efficiency but lowers mitochondrial respiration and reduces the abundance and activities of mitochondrial enzymes (79). Here, we show that muscle *Tsc1* knockout mice have an increased reliance on carbohydrate oxidation (Figure 1G). Taken together, these observations suggest that mTORC1 influences metabolism by increasing mitochondrial enzyme content, the coupling of oxidative phosphorylation to ATP production, and the dissipation of energy via uncoupling of the sarcoplasmic reticulum.

One response to nutrient overload is to promote anabolism, consistent with mTORC1-dependent activation of protein synthesis, lipogenesis, and glycogenesis (43, 51, 60). Thus, it is reasonable to propose that nutrient overload may promote ineffective catabolism as a way of reducing systemic nutrient stress. Examples of this include mTORC1-dependent activation of amino acid catabolism through glutamate dehydrogenase (20, 21), and mTORC1-dependent activation of brown adipose tissue (49, 52, 58, 61, 93). It is notable however that in our model, we do not detect mTORC1 activation in BAT (Supplementary Figure 1). That being said, we are not able to rule out indirect mechanisms linking muscle mTORC1 activity to elevated energy expenditure, such as FGF21, other myokines or muscle-derived metabolites. A dual role of mTORC1 in combatting nutrient excess by promoting both catabolism and anabolism warrants further study.

As noted throughout, there are several similarities between our *Ckmm-Cre* driven *Tsc1*  knockout and the previously published *ACTA1-Cre* driven knockout models (10, 17, 35, 36). Both models report elevated energy expenditure, a higher proportion of oxidative fibers, less adiposity and resilience to diet-induced obesity and insulin resistance. Both models also show signs of elevated ageing including kyphosis and early death. The model reported here is unique in that there is no obvious loss of lean mass with chronic mTORC1 activation. While we observed some similar transcriptional changes including induction of transcripts encoding PGC1, FGF21, BIP and CHOP, we did not observe induction of the atrogenes MuRF1 or Atrogin-1. In our view this reduces the likelihood that the above phenotypes are confounded by impaired muscle function in young mice.

Transcriptional profiling across species has identified downregulation of mitochondrial genes in skeletal muscle as a common aging signature (72, 99), whereas loss of skeletal muscle mitochondrial function is associated with age-related sarcopenia in *C. elegans* (18, 31) and mice. Candidate gene studies on aging have implicated genes with important roles in skeletal muscle metabolism, including *IGF1R*, *AKT1* and *FOXO3A* (70, 90), genes that are also linked to mTORC1 signaling. In humans, polymorphisms in *FOXO3A* have been associated with lengthened lifespan (3, 7, 30, 55, 70, 87, 96), whereas both mouse and fruit fly models of *FOXO3A* loss of function result in stronger and longer living model organisms (33, 42, 65). Indeed, nonagenarians show downregulation of mTOR pathway genes (69), supporting a role for decreased mTOR signaling in human longevity, whereas in rats, inhibition of mTORC1 via rapalog treatment ameliorates age-related sarcopenia (44). Here, we show that despite an apparent increase in the oxidative phenotype of muscle, constituent activation of mTORC1 in skeletal muscle decreases lifespan in mice, a finding in consensus with other models of mTORC1 activation (15, 38, 45). As we detect mTORC1 activation in both cardiac and skeletal muscle, we are not able to exclude the possibility that reduced lifespan is due to age-related cardiac dysfunction.

**5.0 Conclusions**

We have shown that increases in energy expenditure following a high fat diet- are mTORC1-dependent and that elevated energy expenditure caused by ablation of *Tsc1*, and thus constituent activation of skeletal muscle mTORC1, coincides with the upregulation of skeletal muscle-specific thermogenic mechanisms that involve the sarcolipin-driven futile cycling of Ca2+ through SERCA2. These findings support the hypothesis that activation of mTORC1 and its downstream targets, specifically in skeletal muscle, may play a role in adaptive thermogenesis, and point to a role for mTORC1 in stimulating mechanisms of energy expenditure in response to caloric overload. Whether mTORC1-dependent Ca2+ cycling in muscle is an effective therapeutic strategy for targeting weight loss remains to be determined, but given the negative effects of mTORC1 activation on lifespan, clinical utility is expected to be low unless these phenotypes can be separated.

# 6.0 Acknowledgements

The authors would like to thank Melanie Schmitt of the UM Animal Phenotyping Core for assistance with CLAMS and glucose clamp studies on the muscle *Tsc1* knockout mice. William Taylor, Caitlin Costelle and Felicia Waller at the UTHSC Molecular Resource Center provided support for the transcriptomic studies. We would also like to thank the other members of the Bridges, Stephenson, Han, and Saltiel laboratories for helpful discussions regarding this project.

This work was supported by Le Bonheur Grant 650700 (DB), NIH Grants DK107535 (DB), DK076906 and DK117551 (ARS), funds from the Memphis Research Consortium (DB and JCH), the Center for Integrative and Translational Genetics (DB), the UTHSC Department of Physiology Qiugley Award (IH) and a Rackham Merit Fellowship (MCM). This work also utilized Core Services supported by NIH grants DK089503, DK110768, DK020572 and AR069620 to the University of Michigan.

# 7.0 References

1. **Acheson KJ**, **Schutz Y**, **Bessard T**, **Anantharaman K**, **Flatt JP**, **Jequier E**. Glycoprotein storage capacity and de novo lipogenesis during massive carbohydrate overfeeding in man. *Am. J. Clin. Nutr.* 48: 240–247, 1988.

2. **Anders S**, **Pyl PT**, **Huber W**. HTSeq-A Python framework to work with high-throughput sequencing data. *Bioinformatics* 31: 166–169, 2015.

3. **Anselmi CV**, **Malovini A**, **Roncarati R**, **Novelli V**, **Villa F**, **Condorelli G**, **Bellazzi R**, **Puca AA**. Association of the FOXO3A locus with extreme longevity in a southern Italian centenarian study. *Rejuvenation Res* 12: 95–104, 2009.

4. **Ashton RE**, **Tew GA**, **Aning JJ**, **Gilbert SE**, **Lewis L**, **Saxton JM**. Effects of short-term, medium-term and long-term resistance exercise training on cardiometabolic health outcomes in adults: Systematic review with meta-analysis. *Br. J. Sports Med.* (2018). doi: 10.1136/bjsports-2017-098970.

5. **Ayala JE**, **Bracy DP**, **Mcguinness OP**, **Wasserman DH**. Considerations in the Design of Hyperinsulinemic- Euglycemic Clamps in the Conscious Mouse. *Diabetes* 55: 390–397, 2006.

6. **Bal NC**, **Maurya SK**, **Sopariwala DH**, **Sahoo SK**, **Gupta SC**, **Shaikh SA**, **Pant M**, **Rowland LA**, **Goonasekera SA**, **Molkentin JD**, **Periasamy M**. Sarcolipin is a newly identified regulator of muscle-based thermogenesis in mammals. *Nat Med* 18: 1575–9, 2012.

7. **Bao J-M**, **Song X-L**, **Hong Y-Q**, **Zhu H-L**, **Li C**, **Zhang T**, **Chen W**, **Zhao S-C**, **Chen Q**. Association between FOXO3A gene polymorphisms and human longevity: a meta-analysis. *Asian J Androl* 16: 446–52, 2014.

8. **Bates DM**, **Mächler M**, **Bolker B**, **Walker S**. Fitting Linear Mixed-Effects Models using lme4. *ArXiv* 1406.5823: 1–51, 2014.

9. **Benjamini Y**, **Hochberg Y**. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *J R Stat Soc Ser B* 57: 289–300, 1995.

10. **Bentzinger CF**, **Lin S**, **Romanino K**, **Castets P**, **Guridi M**, **Summermatter S**, **Handschin C**, **Tintignac LA**, **Hall MN**, **Rüegg MA**. Differential response of skeletal muscles to mTORC1 signaling during atrophy and hypertrophy. *Skelet Muscle* 3: 6, 2013.

11. **Bentzinger CF**, **Romanino K**, **Cloëtta D**, **Lin S**, **Mascarenhas JB**, **Oliveri F**, **Xia J**, **Casanova E**, **Costa CF**, **Brink M**, **Zorzato F**, **Hall MN**, **Rüegg MA**. Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. *Cell Metab* 8: 411–24, 2008.

12. **Berg CE**, **Lavan BE**, **Rondinone CM**. Rapamycin partially prevents insulin resistance induced by chronic insulin treatment. *Biochem Biophys Res Commun* 293: 1021–1027, 2002.

13. **van den Berg SA**, **van Marken Lichtenbelt W**, **Willems van Dijk K**, **Schrauwen P**. Skeletal muscle mitochondrial uncoupling, adaptive thermogenesis and energy expenditure. *Curr Opin Clin Nutr Metab Care* 14: 243–249, 2011.

14. **Bilanges B**, **Argonza-Barrett R**, **Kolesnichenko M**, **Skinner C**, **Nair M**, **Chen M**, **Stokoe D**. Tuberous sclerosis complex proteins 1 and 2 control serum-dependent translation in a TOP-dependent and -independent manner. *Mol Cell Biol* 27: 5746–5764, 2007.

15. **Bjedov I**, **Toivonen JM**, **Kerr F**, **Slack C**, **Jacobson J**, **Foley A**, **Partridge L**. Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. *Cell Metab* 11: 35–46, 2010.

16. **Bombardier E**, **Smith IC**, **Gamu D**, **Fajardo VA**, **Vigna C**, **Sayer RA**, **Gupta SC**, **Bal NC**, **Periasamy M**, **Tupling AR**. Sarcolipin trumps β-adrenergic receptor signaling as the favored mechanism for muscle-based diet-induced thermogenesis. *FASEB J* 27: 3871–3878, 2013.

17. **Castets P**, **Lin S**, **Rion N**, **Di Fulvio S**, **Romanino K**, **Guridi M**, **Frank S**, **Tintignac LAA**, **Sinnreich M**, **Rüegg MA**, **Di Fulvio S**, **R??egg MA**. Sustained activation of mTORC1 in skeletal muscle inhibits constitutive and starvation-induced autophagy and causes a severe, late-onset myopathy. *Cell Metab* 17: 731–44, 2013.

18. **Castro-Sepúlveda M**, **Tevy MF**, **Jaimovich E**, **Campos CA**, **Eisner V**, **Figueroa R**, **del Campo A**, **Contreras-Hernández I**, **Casas M**. Muscle function decline and mitochondria changes in middle age precede sarcopenia in mice. *Aging (Albany NY)* 10: 34–55, 2018.

19. **Chakrabarti P**, **English T**, **Shi J**, **Smas CM**, **Kandror K V.** Mammalian target of rapamycin complex 1 suppresses lipolysis, stimulates lipogenesis, and promotes fat storage. *Diabetes* 59: 775–781, 2010.

20. **Csibi A**, **Fendt S-M**, **Li C**, **Poulogiannis G**, **Choo AY**, **Chapski DJ**, **Jeong SM**, **Dempsey JM**, **Parkhitko A**, **Morrison T**, **Henske EP**, **Haigis MC**, **Cantley LC**, **Stephanopoulos G**, **Yu J**, **Blenis J**. The mTORC1 Pathway Stimulates Glutamine Metabolism and Cell Proliferation by Repressing SIRT4. *Cell* 153: 840–54, 2013.

21. **Csibi A**, **Lee G**, **Yoon SO**, **Tong H**, **Ilter D**, **Elia I**, **Fendt SM**, **Roberts TM**, **Blenis J**. The mTORC1/S6K1 pathway regulates glutamine metabolism through the eif4b-dependent control of c-Myc translation. *Curr Biol* 24: 2274–2280, 2014.

22. **Cunningham JT**, **Rodgers JT**, **Arlow DH**, **Vazquez F**, **Mootha VK**, **Puigserver P**. mTOR controls mitochondrial oxidative function through a YY1-PGC-1alpha transcriptional complex. *Nature* 450: 736–740, 2007.

23. **DeFronzo RA**, **Ferrannini E**, **Sato Y**, **Felig P**, **Wahren J**. Synergistic interaction between exercise and insulin on peripheral glucose uptake. *J Clin Invest* 68: 1468–74, 1981.

24. **Diaz EO**, **Prentice AM**, **Goldberg GR**, **Murgatroyd PR**, **Coward WA**. Metabolic response to experimental overfeeding in lean and overweight healthy volunteers. *Am J Clin Nutr* 56: 641–655, 1992.

25. **Dutchak PA**, **Estill-Terpack SJ**, **Plec AA**, **Zhao X**, **Yang C**, **Chen J**, **Ko B**, **Deberardinis RJ**, **Yu Y**, **Tu BP**. Loss of a Negative Regulator of mTORC1 Induces Aerobic Glycolysis and Altered Fiber Composition in Skeletal Muscle. *Cell Rep* 23: 1907–1914, 2018.

26. **Düvel K**, **Yecies JL**, **Menon S**, **Raman P**, **Lipovsky AI**, **Souza AL**, **Triantafellow E**, **Ma Q**, **Gorski R**, **Cleaver S**, **Vander Heiden MG**, **MacKeigan JP**, **Finan PM**, **Clish CB**, **Murphy LO**, **Manning BD**. Activation of a Metabolic Gene Regulatory Network Downstream of mTOR Complex 1. *Mol Cell* 39: 171–183, 2010.

27. **Efeyan A**, **Comb WC**, **Sabatini DM**. Nutrient-sensing mechanisms and pathways. *Nature* 517: 302–310, 2015.

28. **Erbay E**, **Chen J**. The mammalian target of rapamycin regulates C2C12 myogenesis via a kinase-independent mechanism. *J Biol Chem* 276: 36079–82, 2001.

29. **Fiatarone MA**. High-Intensity Strength Training in Nonagenarians. *JAMA* 263: 3029, 1990.

30. **Flachsbart F**, **Caliebe A**, **Kleindorp R**, **Blanché H**, **von Eller-Eberstein H**, **Nikolaus S**, **Schreiber S**, **Nebel A**. Association of FOXO3A variation with human longevity confirmed in German centenarians. *Proc Natl Acad Sci U S A* 106: 2700–2705, 2009.

31. **Gaffney CJ**, **Pollard A**, **Barratt TF**, **Constantin-Teodosiu D**, **Greenhaff PL**, **Szewczyk NJ**. Greater loss of mitochondrial function with ageing is associated with earlier onset of sarcopenia in C. elegans. *Aging (Albany NY)* 10: 3382–3396, 2018.

32. **Gale CR**, **Martyn CN**, **Cooper C**, **Sayer AA**. Grip strength, body composition, and mortality. *Int J Epidemiol* 36: 228–235, 2007.

33. **Giannakou ME**, **Goss M**, **Jünger MA**, **Hafen E**, **Leevers SJ**, **Partridge L**. Long-lived Drosophila with overexpressed dFOXO in adult fat body. *Science (80- )* 305: 361, 2004.

34. **Graber TG**, **Fry CS**, **Brightwell CR**, **Moro T**, **Maroto R**, **Bhattari N**, **Porter C**, **Wakamiya M**, **Rasmussen BB**. Skeletal Muscle Specific Knockout of DEP-like domain-containing 5 Increases mTORC1 Signaling, Muscle Cell Hypertrophy, and Mitochondrial Respiration. *J Biol Chem* 294: 4091–4102, 2019.

35. **Guridi M**, **Kupr B**, **Romanino K**, **Lin S**, **Falcetta D**, **Tintignac L**, **Rüegg MA**. Alterations to mTORC1 signaling in the skeletal muscle differentially affect whole-body metabolism. *Skelet Muscle* 6: 13, 2016.

36. **Guridi M**, **Tintignac LA**, **Lin S**, **Kupr B**, **Castets P**, **Rüegg MA**. Activation of mTORC1 in skeletal muscle regulates whole-body metabolism through FGF21. *Sci Signal* 8: ra113–ra113, 2015.

37. **Halseth AMYE**, **Bracy DP**, **Wasserman DH**, **Amy E**, **Bracy DP**, **David H**. Overexpression of hexokinase II increases insulin- and exercise-stimulated muscle glucose uptake in vivo. *Am J Physiol* 276: E70-77, 1999.

38. **Harrison DE**, **Strong R**, **Sharp ZD**, **Nelson JF**, **Astle CM**, **Flurkey K**, **Nadon NL**, **Wilkinson JE**, **Frenkel K**, **Carter CS**, **Pahor M**, **Javors MA**, **Fernandez E**, **Miller RA**. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. *Nature* 460: 392–5, 2009.

39. **Harvey I**, **Stephenson EJ**, **Redd JR**, **Tran QT**, **Hochberg I**, **Qi N**, **Bridges D**. Glucocorticoid-Induced Metabolic Disturbances Are Exacerbated in Obese Male Mice. *Endocrinology* 159: 2275–2287, 2018.

40. **Hatfield I**, **Harvey I**, **Yates ER**, **Redd JR**, **Reiter LT**, **Bridges D**. The role of TORC1 in muscle development in Drosophila. *Sci Rep* 5: 9676, 2015.

41. **Heinitz S**, **Hollstein T**, **Ando T**, **Walter M**, **Basolo A**, **Krakoff J**, **Votruba SB**, **Piaggi P**. Early Adaptive Thermogenesis Is a Determinant of Weight Loss after Six Weeks of Caloric Restriction in Overweight Subjects. *Metabolism* : 154303, 2020.

42. **Hwangbo DS**, **Gershman B**, **Tu M-P**, **Palmer M**, **Tatar M**. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. *Nature* 429: 562–566, 2004.

43. **Iadevaia V**, **Huo Y**, **Zhang Z**, **Foster LJ**, **Proud CG**. Roles of the mammalian target of rapamycin, mTOR, in controlling ribosome biogenesis and protein synthesis: Figure 1. *Biochem Soc Trans* 40: 168–172, 2012.

44. **Joseph GA**, **Wang S**, **Jacobs CE**, **Zhou W**, **Kimble GC**, **Tse HW**, **Eash JK**, **Shavlakadze T**, **Glass DJ**. Partial inhibition of mTORC1 in aged rats counteracts the decline in muscle mass and reverses molecular signaling associated with sarcopenia. *Mol. Cell. Biol.* ( July 15, 2019). doi: 10.1128/MCB.00141-19.

45. **Kapahi P**, **Zid BM**, **Harper T**, **Koslover D**, **Sapin V**, **Benzer S**. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. *Curr Biol* 14: 885–90, 2004.

46. **Kim D**, **Pertea G**, **Trapnell C**, **Pimentel H**, **Kelley R**, **Salzberg SL**. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* 14: R36, 2013.

47. **Koyanagi M**, **Asahara S-I**, **Matsuda T**, **Hashimoto N**, **Shigeyama Y**, **Shibutani Y**, **Kanno A**, **Fuchita M**, **Mikami T**, **Hosooka T**, **Inoue H**, **Matsumoto M**, **Koike M**, **Uchiyama Y**, **Noda T**, **Seino S**, **Kasuga M**, **Kido Y**. Ablation of TSC2 enhances insulin secretion by increasing the number of mitochondria through activation of mTORC1. *PLoS One* 6, 2011.

48. **Kraegen E**, **James D**, **Jenkins A**, **Chisholm D**. Dose-response curves for in vivo insulin sensitivity in individual tissues in rats. *Am Physiol Soc* : E353–E362, 1985.

49. **Labbé SM**, **Mouchiroud M**, **Caron A**, **Secco B**, **Freinkman E**, **Lamoureux G**, **Gélinas Y**, **Lecomte R**, **Bossé Y**, **Chimin P**, **Festuccia WT**, **Richard D**, **Laplante M**. mTORC1 is Required for Brown Adipose Tissue Recruitment and Metabolic Adaptation to Cold. *Sci Rep* 6: 37223, 2016.

50. **Langmead B**, **Trapnell C**, **Pop M**, **Salzberg SL**. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol* 10: R25, 2009.

51. **Laplante M**, **Sabatini DM**. mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. *Proc Natl Acad Sci U S A* 107: 3281–2, 2010.

52. **Lee PL**, **Tang Y**, **Li H**, **Guertin DA**. Raptor/mTORC1 loss in adipocytes causes progressive lipodystrophy and fatty liver disease. *Mol Metab* 5: 422–432, 2016.

53. **Leibel RL**, **Rosenbaum M**, **Hirsch J**. Changes in energy expenditure resulting from altered body weight. *N Engl J Med* 332: 621–8, 1995.

54. **Li S**, **Brown MS**, **Goldstein JL**. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. *Proc Natl Acad Sci U S A* 107: 3441–6, 2010.

55. **Li Y**, **Wang WJ**, **Cao H**, **Lu J**, **Wu C**, **Hu FY**, **Guo J**, **Zhao L**, **Yang F**, **Zhang YX**, **Li W**, **Zheng GY**, **Cui H**, **Chen X**, **Zhu Z**, **He H**, **Dong B**, **Mo X**, **Zeng Y**, **Tian XL**. Genetic association of FOXO1A and FOXO3A with longevity trait in Han Chinese populations. *Hum Mol Genet* 18: 4897–4904, 2009.

56. **Liberzon A**, **Subramanian A**, **Pinchback R**, **Thorvaldsdóttir H**, **Tamayo P**, **Mesirov JP**. Molecular signatures database (MSigDB) 3.0. *Bioinformatics* 27: 1739–1740, 2011.

57. **Ling CHY**, **Taekema D**, **De Craen AJM**, **Gussekloo J**, **Westendorp RGJ**, **Maier AB**. Handgrip strength and mortality in the oldest old population: The Leiden 85-plus study. *Cmaj* 182: 429–435, 2010.

58. **Liu D**, **Bordicchia M**, **Zhang C**, **Fang H**, **Wei W**, **Li J-LL**, **Guilherme A**, **Guntur K**, **Czech MP**, **Collins S**. Activation of mTORC1 is essential for β-adrenergic stimulation of adipose browning. *J Clin Invest* 1: 1–13, 2016.

59. **Love MI**, **Huber W**, **Anders S**. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15: 550, 2014.

60. **Lu B**, **Bridges D**, **Yang Y**, **Fisher K**, **Cheng A**, **Chang L**, **Meng Z**, **Lin JD**, **Downes M**, **Yu RT**, **Liddle C**, **Evans RM**, **Saltiel AR**. Metabolic crosstalk: molecular links between glycogen and lipid metabolism in obesity. *Diabetes* 63: 2935–48, 2014.

61. **Magdalon J**, **Chimin P**, **Belchior T**, **Neves RX**, **Vieira-Lara MA**, **Andrade ML**, **Farias TS**, **Bolsoni-Lopes A**, **Paschoal VA**, **Yamashita AS**, **Kowaltowski AJ**, **Festuccia WT**. Constitutive adipocyte mTORC1 activation enhances mitochondrial activity and reduces visceral adiposity in mice. *Biochim Biophys Acta - Mol Cell Biol Lipids* 1861: 430–438, 2016.

62. **Maurya SK**, **Periasamy M**. Sarcolipin is a novel regulator of muscle metabolism and obesity. *Pharmacol Res* 102: 270–5, 2015.

63. **McGuinness OP**, **Ayala JE**, **Laughlin MR**, **Wasserman DH**. NIH experiment in centralized mouse phenotyping: the Vanderbilt experience and recommendations for evaluating glucose homeostasis in the mouse. *Am J Physiol - Endocrinol Metab* 297, 2009.

64. **Metter EJ**, **Talbot L a**, **Schrager M**, **Conwit R**. Skeletal muscle strength as a predictor of all-cause mortality in healthy men. *Journals Gerontol Ser A Biol Sci Med Sci* 57: B359–B365, 2002.

65. **Milan G**, **Romanello V**, **Pescatore F**, **Armani A**, **Paik J-H**, **Frasson L**, **Seydel A**, **Zhao J**, **Abraham R**, **Goldberg AL**, **Blaauw B**, **DePinho R a.**, **Sandri M**. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy. *Nat Commun* 6: 6670, 2015.

66. **Ozcan U**, **Ozcan L**, **Yilmaz E**, **Düvel K**, **Sahin M**, **Manning BD**, **Hotamisligil GS**. Loss of the Tuberous Sclerosis Complex Tumor Suppressors Triggers the Unfolded Protein Response to Regulate Insulin Signaling and Apoptosis. *Mol Cell* 29: 541–551, 2008.

67. **Pacher M**, **Seewald MJ**, **Mikula M**, **Oehler S**, **Mogg M**, **Vinatzer U**, **Eger A**, **Schweifer N**, **Varecka R**, **Sommergruber W**, **Mikulits W**, **Schreiber M**. Impact of constitutive IGF1/IGF2 stimulation on the transcriptional program of human breast cancer cells. *Carcinogenesis* 28: 49–59, 2007.

68. **Paran CW**, **Verkerke ARP**, **Heden TD**, **Park S**, **Zou K**, **Lawson HA**, **Song H**, **Turk J**, **Houmard JA**, **Funai K**. Reduced efficiency of sarcolipin-dependent respiration in myocytes from humans with severe obesity. *Obesity (Silver Spring)* 23: 1440–9, 2015.

69. **Passtoors WM**, **Beekman M**, **Deelen J**, **van der Breggen R**, **Maier AB**, **Guigas B**, **Derhovanessian E**, **van Heemst D**, **de Craen AJM**, **Gunn DA**, **Pawelec G**, **Slagboom PE**. Gene expression analysis of mTOR pathway: Association with human longevity. *Aging Cell* 12: 24–31, 2013.

70. **Pawlikowska L**, **Hu D**, **Huntsman S**, **Sung A**, **Chu C**, **Chen J**, **Joyner AH**, **Schork NJ**, **Hsueh W-CC**, **Reiner AP**, **Psaty BM**, **Atzmon G**, **Barzilai N**, **Cummings SR**, **Browner WS**, **Kwok P-YY**, **Ziv E**, **Study of Osteoporotic Fractures**. Association of common genetic variation in the insulin/IGF1 signaling pathway with human longevity. *Aging Cell* 8: 460–72, 2009.

71. **Péronnet F**, **Massicotte D**. Table of nonprotein respiratory quotient: an update. *Can J Sport Sci* 16: 23–9, 1991.

72. **Phillips BE**, **Williams JP**, **Gustafsson T**, **Bouchard C**, **Rankinen T**, **Knudsen S**, **Smith K**, **Timmons JA**, **Atherton PJ**. Molecular Networks of Human Muscle Adaptation to Exercise and Age. *PLoS Genet* 9, 2013.

73. **Philp A**, **Schenk S**, **Perez-Schindler J**, **Hamilton DL**, **Breen L**, **Laverone E**, **Jeromson S**, **Phillips SM**, **Baar K**. Rapamycin does not prevent increases in myofibrillar or mitochondrial protein synthesis following endurance exercise. *J Physiol* 44: n/a-n/a, 2015.

74. **R Core Team**. R: A Language and Environment for Statistical Computing. 2019.

75. **Ramanathan A**, **Schreiber SL**. Direct control of mitochondrial function by mTOR. *Proc Natl Acad Sci U S A* 106: 22229–22232, 2009.

76. **Rantanen T**, **Harris TB**, **Leveille SG**, **Visser M**, **Foley D**, **Masaki K**, **Guralnik JM**. Muscle strength and body mass index as long-term predictors of mortality in initially healthy men. *Journals Gerontol Ser A Biol Sci Med Sci* 55: M168–M173, 2000.

77. **Rantanen T**, **Volpato S**, **Ferrucci L**, **Heikkinen E**, **Fried LP**, **Guralnik JM**. Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism. *J Am Geriatr Soc* 51: 636–641, 2003.

78. **Reinhardt M**, **Thearle MS**, **Ibrahim M**, **Hohenadel MG**, **Bogardus C**, **Krakoff J**, **Votruba SB**. A Human Thrifty Phenotype Associated With Less Weight Loss During Caloric Restriction. *Diabetes* 64: db141881, 2015.

79. **Risson V**, **Mazelin L**, **Roceri M**, **Sanchez H**, **Moncollin V**, **Corneloup C**, **Richard-Bulteau H**, **Vignaud A**, **Baas D**, **Defour A**, **Freyssenet D**, **Tanti J-F**, **Le-Marchand-Brustel Y**, **Ferrier B**, **Conjard-Duplany A**, **Romanino K**, **Bauché S**, **Hantaï D**, **Mueller M**, **Kozma SC**, **Thomas G**, **Rüegg MA**, **Ferry A**, **Pende M**, **Bigard X**, **Koulmann N**, **Schaeffer L**, **Gangloff Y-G**. Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. *J Cell Biol* 187: 859–74, 2009.

80. **Rolfe DF**, **Brown GC**. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. *Physiol Rev* 77: 731–758, 1997.

81. **Rowland LA**, **Maurya SK**, **Bal NC**, **Kozak L**, **Periasamy M**. Sarcolipin and uncoupling protein 1 play distinct roles in diet-induced thermogenesis and do not compensate for one another. *Obesity* 00: 10–13, 2016.

82. **Sahoo SK**, **Shaikh SA**, **Sopariwala DH**, **Bal NC**, **Periasamy M**. Sarcolipin Protein Interaction with Sarco(endo)plasmic Reticulum Ca2+ATPase (SERCA) Is Distinct from Phospholamban Protein, and Only Sarcolipin Can Promote Uncoupling of the SERCA Pump. *J Biol Chem* 288: 6881–6889, 2013.

83. **Sasaki H**, **Kasagi F**, **Yamada M**, **Fujita S**. Grip strength predicts cause-specific mortality in middle-aged and elderly persons. *Am J Med* 120: 337–342, 2007.

84. **Shah OJ**, **Wang Z**, **Hunter T**. Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies. *Curr Biol* 14: 1650–6, 2004.

85. **Sipula IJ**, **Brown NF**, **Perdomo G**. Rapamycin-mediated inhibition of mammalian target of rapamycin in skeletal muscle cells reduces glucose utilization and increases fatty acid oxidation. *Metabolism* 55: 1637–1644, 2006.

86. **Smith WS**, **Broadbridge R**, **East JM**, **Lee AG**. Sarcolipin uncouples hydrolysis of ATP from accumulation of Ca2+ by the Ca2+-ATPase of skeletal-muscle sarcoplasmic reticulum. *Biochem J* 361: 277–286, 2002.

87. **Soerensen M**, **Dato S**, **Christensen K**, **McGue M**, **Stevnsner T**, **Bohr V a.**, **Christiansen L**. Replication of an association of variation in the FOXO3A gene with human longevity using both case-control and longitudinal data. *Aging Cell* 9: 1010–1017, 2010.

88. **Stephenson EJ**, **Ragauskas A**, **Jaligama S**, **Redd JR**, **Parvathareddy J**, **Peloquin MJMJ**, **Saravia J**, **Han JC**, **Cormier SA**, **Bridges D**. Exposure to environmentally persistent free radicals during gestation lowers energy expenditure and impairs skeletal muscle mitochondrial function in adult mice. *Am J Physiol - Endocrinol Metab* 310: ajpendo.00521.2015, 2016.

89. **Subramanian A**, **Tamayo P**, **Mootha VK**, **Mukherjee S**, **Ebert BL**, **Gillette MA**, **Paulovich A**, **Pomeroy SL**, **Golub TR**, **Lander ES**, **Mesirov JP**. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A* 102: 15545–50, 2005.

90. **Suh Y**, **Atzmon G**, **Cho M-O**, **Hwang D**, **Liu B**, **Leahy DJ**, **Barzilai N**, **Cohen P**. Functionally significant insulin-like growth factor I receptor mutations in centenarians. *Proc Natl Acad Sci U S A* 105: 3438–42, 2008.

91. **Therneau T**. A Package for Survival Analysis in S. R package version. *Survival (Lond).*: 2012.

92. **Therneau TM**, **Grambsch PM**. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer New York, 2000.

93. **Tran CM**, **Mukherjee S**, **Ye L**, **Frederick DW**, **Kissig M**, **Davis JG**, **Lamming DW**, **Seale P**, **Baur JA**. Rapamycin blocks induction of the thermogenic program in white adipose tissue. *Diabetes* 65: 1–35, 2016.

94. **Tremblay F**, **Marette A**. Amino acid and insulin signaling via the mTOR/p70 S6 kinase pathway. A negative feedback mechanism leading to insulin resistance in skeletal muscle cells. *J Biol Chem* 276: 38052–60, 2001.

95. **Tschöp MH**, **Speakman JR**, **Arch JRS**, **Auwerx J**, **Brüning JC**, **Chan L**, **Eckel RH**, **Farese R V**, **Galgani JE**, **Hambly C**, **Herman M a**, **Horvath TL**, **Kahn BB**, **Kozma SC**, **Maratos-Flier E**, **Müller TD**, **Münzberg H**, **Pfluger PT**, **Plum L**, **Reitman ML**, **Rahmouni K**, **Shulman GI**, **Thomas G**, **Kahn CR**, **Ravussin E**. A guide to analysis of mouse energy metabolism. *Nat Methods* 9: 57–63, 2011.

96. **Willcox BJ**, **Donlon T a**, **He Q**, **Chen R**, **Grove JS**, **Yano K**, **Masaki KH**, **Willcox DC**, **Rodriguez B**, **Curb JD**. FOXO3A genotype is strongly associated with human longevity. *Proc Natl Acad Sci U S A* 105: 13987–13992, 2008.

97. **World Health Organization**. Obesity and Overweight [Online]. 2013. http://www.who.int/mediacentre/factsheets/fs311/en/.

98. **Yecies JL**, **Zhang HH**, **Menon S**, **Liu S**, **Yecies D**, **Lipovsky AI**, **Gorgun C**, **Kwiatkowski DJ**, **Hotamisligil GS**, **Lee C-H**, **Manning BD**. Akt Stimulates Hepatic SREBP1c and Lipogenesis through Parallel mTORC1-Dependent and Independent Pathways. *Cell Metab* 14: 21–32, 2011.

99. **Zahn JM**, **Sonu R**, **Vogel H**, **Crane E**, **Mazan-Mamczarz K**, **Rabkin R**, **Davis RW**, **Becker KG**, **Owen AB**, **Kim SK**. Transcriptional profiling of aging in human muscle reveals a common aging signature. *PLoS Genet* 2: 1058–1069, 2006.

100. **Zhang HH**, **Huang J**, **Düvel K**, **Boback B**, **Wu S**, **Squillace RM**, **Wu C-L**, **Manning BD**. Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. *PLoS One* 4: e6189, 2009.

# Figure Legends

**Figure 1: mTORC1 regulates energy expenditure.** A) Summary of the rapamycin/high fat diet experimental protocol, and its effect on B) energy expenditure and C) ambulatory activity of 10-week-old male C57BL/6J mice. D) Total energy expenditure, E) ambulatory activity, F) respiratory exchange ratios (RER) and G) rates of carbohydrate oxidation and H) fat oxidation of 10-week-old mice with *Ckmm-Cre* driven knockout of *Tsc1* and their control littermates. H) Absolute food intake of muscle *Tsc1-*knockout mice and their control littermates that received either normal chow diet (NCD) or a high fat diet (HFD). Food intake data were determined over 4-12 weeks on a per-cage basis for mice housed by genotype (n=5-20/group).

**Figure 2: Skeletal muscle mTORC1 activation attenuates age-associated gains in adiposity.** A) Body Weight, B) Total body fat and C) lean mass of male mice with *Ckmm-Cre* driven knockout of *Tsc1* and their control littermates, as determined longitudinally, from the age of weaning until 29-weeks of age. D) Weights of the dorsolumbar-inguinal and gonadal fat depots. E) Blood glucose curves during an tolerance test and F) the glucose infusion, glucose turnover and endogenous glucose production rates during a hyperinsulinemic euglycemic clamp. G) Tissue 2-deoxyglucose uptake under insulin stimulated conditions at the end of the clamp. Statistical significance is denoted by asterisks indicating p<0.05, based on a likelihood ratio test (B) or Mann-Whitney test (D and G, due to lack of normality). Data are reported for n=7 muscle *Tsc1* knockout mice and n=25 control mice. Mice were fasted 5-6 hours prior to insulin tolerance tests and hyperinsulinemic clamp studies.

**Figure 3: Skeletal muscle mTORC1 activation protects against diet-induced obesity and insulin resistance.** A) Total body weight, B) total body fat and C) total lean mass of male and female mice with *Ckmm-Cre* driven knockout of *Tsc1* and their control littermates following 11-weeks of an obesogenic diet containing 45% energy from fat (HFD), beginning at 10-weeks of age. D) Weights of the dorsolumbar-inguinal and gonadal fat depots after 11-weeks of HFD. E) Blood glucose concentration curves during an insulin tolerance test in 6 hour-fasted male and female mice with *Ckmm-Cre* driven knockout of *Tsc1* and their control littermates after 11-weeks of HFD. Statistical significance (\*p<0.05, n=5/7) was determined via a Welch’s *t* test (D, males), or a Mann-Whitney test (D, females, due to lack of normality).

**Figure 4: Skeletal muscle mTORC1 activation alters the transcriptional regulation of nutrient uptake and oxidative capacity.** A) Expression of amino acid transporters B) fatty acid transporters, C) Ca2+ trafficking and, markers of fiber type E) as determined by RNAseq. D) Representative protein expression of S6 phosphorylation at Ser236/236, total S6 and sarcolipin in quadriceps muscles from male control mice and mice with *Ckmm-Cre* driven knockout of *Tsc1*. F) Representative images of quadriceps muscle from mice with *Ckmm-Cre* driven knockout of *Tsc1* and their control littermates stained for NADH-tetrazolium reductase, where oxidative fibers stain darkest. Asterisks indicates adjusted p-values of <0.05.

**Figure 5: Skeletal muscle mTORC1 activation reduces lifespan in mice.**

Survival curve of male muscle *Tsc1* knockout mice on a normal chow diet.Dotted lines indicate age at which 50% of animals died.

# Supplementary Figure and Table Legends

**Supplementary Figure 1: mTORC1 activation in muscle *Tsc1* knockout tissues.** Western blotting of multiple muscle and non-muscle tissues for phosphorylated and total S6. Representative blots of n=4/group.

**Supplementary Table 1: Gene expression differences in muscle *Tsc1* knockout quadriceps.** Full results of differential expression analysis.

**Supplementary Table 2: Gene set enrichment analysis of *Tsc1* knockout quadriceps.** All pathways that met an adjusted p-value of 0.25 are shown. NES (normalized enrichment score) indicates pathway effect size with positive numbers indicating positive enrichment of this gene set in these data. Gene details are the genes which drove this positive or negative association. Both nominal (NOM) and FDR adjusted (FDR) p/q values are shown.